Details
Stereochemistry | ACHIRAL |
Molecular Formula | C16H21N3 |
Molecular Weight | 255.358 |
Optical Activity | NONE |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
CN(C)CCN(CC1=CC=CC=C1)C2=CC=CC=N2
InChI
InChIKey=UFLGIAIHIAPJJC-UHFFFAOYSA-N
InChI=1S/C16H21N3/c1-18(2)12-13-19(16-10-6-7-11-17-16)14-15-8-4-3-5-9-15/h3-11H,12-14H2,1-2H3
Molecular Formula | C16H21N3 |
Molecular Weight | 255.358 |
Charge | 0 |
Count |
|
Stereochemistry | ACHIRAL |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Optical Activity | NONE |
DescriptionSources: https://www.drugs.com/mtm/tripelennamine.html
Sources: https://www.drugs.com/mtm/tripelennamine.html
Tripelennamine (sold as Pyribenzamine by Novartis) is a drug that is used as an antipruritic and first-generation antihistamine. Histamine acting on H1-receptors produces vasodilatation, hypotension, flushing, headache, tachycardia, and bronchoconstriction. Histamine also increases vascular permeability and potentiates pain. Tripelennamine can be used in the treatment of asthma, hay fever, rhinitis, and urticaria, but is now less common as newer antihistamines have replaced it.
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL231 Sources: https://www.ncbi.nlm.nih.gov/pubmed/7513381 |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Sources: https://www.drugs.com/mtm/tripelennamine.html |
Palliative | PBZ Approved UseUnknown Launch Date1948 |
||
Sources: https://www.drugs.com/mtm/tripelennamine.html |
Palliative | PBZ Approved UseUnknown Launch Date1948 |
||
Palliative | PBZ Approved UseUnknown Launch Date1948 |
Cmax
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
82 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/3709032 |
50 mg single, intramuscular dose: 50 mg route of administration: Intramuscular experiment type: SINGLE co-administered: |
TRIPELENNAMINE plasma | Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN |
|
199 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/3709032 |
100 mg single, intramuscular dose: 100 mg route of administration: Intramuscular experiment type: SINGLE co-administered: |
TRIPELENNAMINE plasma | Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN |
AUC
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
398 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/3709032 |
50 mg single, intramuscular dose: 50 mg route of administration: Intramuscular experiment type: SINGLE co-administered: |
TRIPELENNAMINE plasma | Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN |
|
804 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/3709032 |
100 mg single, intramuscular dose: 100 mg route of administration: Intramuscular experiment type: SINGLE co-administered: |
TRIPELENNAMINE plasma | Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN |
T1/2
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
2.9 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/3709032 |
50 mg single, intramuscular dose: 50 mg route of administration: Intramuscular experiment type: SINGLE co-administered: |
TRIPELENNAMINE plasma | Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN |
|
4.4 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/3709032 |
100 mg single, intramuscular dose: 100 mg route of administration: Intramuscular experiment type: SINGLE co-administered: |
TRIPELENNAMINE plasma | Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN |
Doses
Dose | Population | Adverse events |
---|---|---|
100 mg 1 times / day single, oral Studied dose Dose: 100 mg, 1 times / day Route: oral Route: single Dose: 100 mg, 1 times / day Sources: |
healthy, 2 years n = 1 Health Status: healthy Age Group: 2 years Sex: F Population Size: 1 Sources: |
Other AEs: Weakness, Common cold... Other AEs: Weakness Sources: Common cold (grade 1) Cough Rhinorrhea Vomiting Sleepiness |
25 mg 3 times / day multiple, oral Studied dose Dose: 25 mg, 3 times / day Route: oral Route: multiple Dose: 25 mg, 3 times / day Co-administed with:: antistin(50 mg; 11 days) Sources: |
unhealthy, 49 years n = 1 Health Status: unhealthy Condition: chronic allergic rhinitis Age Group: 49 years Sex: F Population Size: 1 Sources: |
Other AEs: Coma, Common cold... Other AEs: Coma Sources: Common cold Nausea Diarrhoea Back pain Headache (grade 3) Appetite lost Dry cough Pyrexia Abdominal pain (grade 3) Vomiting Disorientation |
50 mg 3 times / day multiple, oral Recommended Dose: 50 mg, 3 times / day Route: oral Route: multiple Dose: 50 mg, 3 times / day Sources: |
unhealthy, median age 36 years n = 90 Health Status: unhealthy Condition: chronic allergic rhinitis Age Group: median age 36 years Sex: M+F Population Size: 90 Sources: |
Other AEs: Sedation, Sedation... Other AEs: Sedation (grade 1, 8.9%) Sources: Sedation (grade 2, 6.7%) Dizziness (5.5%) Nausea (4.4%) Nose dryness (2.2%) |
AEs
AE | Significance | Dose | Population |
---|---|---|---|
Cough | 100 mg 1 times / day single, oral Studied dose Dose: 100 mg, 1 times / day Route: oral Route: single Dose: 100 mg, 1 times / day Sources: |
healthy, 2 years n = 1 Health Status: healthy Age Group: 2 years Sex: F Population Size: 1 Sources: |
|
Rhinorrhea | 100 mg 1 times / day single, oral Studied dose Dose: 100 mg, 1 times / day Route: oral Route: single Dose: 100 mg, 1 times / day Sources: |
healthy, 2 years n = 1 Health Status: healthy Age Group: 2 years Sex: F Population Size: 1 Sources: |
|
Sleepiness | 100 mg 1 times / day single, oral Studied dose Dose: 100 mg, 1 times / day Route: oral Route: single Dose: 100 mg, 1 times / day Sources: |
healthy, 2 years n = 1 Health Status: healthy Age Group: 2 years Sex: F Population Size: 1 Sources: |
|
Vomiting | 100 mg 1 times / day single, oral Studied dose Dose: 100 mg, 1 times / day Route: oral Route: single Dose: 100 mg, 1 times / day Sources: |
healthy, 2 years n = 1 Health Status: healthy Age Group: 2 years Sex: F Population Size: 1 Sources: |
|
Weakness | 100 mg 1 times / day single, oral Studied dose Dose: 100 mg, 1 times / day Route: oral Route: single Dose: 100 mg, 1 times / day Sources: |
healthy, 2 years n = 1 Health Status: healthy Age Group: 2 years Sex: F Population Size: 1 Sources: |
|
Common cold | grade 1 | 100 mg 1 times / day single, oral Studied dose Dose: 100 mg, 1 times / day Route: oral Route: single Dose: 100 mg, 1 times / day Sources: |
healthy, 2 years n = 1 Health Status: healthy Age Group: 2 years Sex: F Population Size: 1 Sources: |
Appetite lost | 25 mg 3 times / day multiple, oral Studied dose Dose: 25 mg, 3 times / day Route: oral Route: multiple Dose: 25 mg, 3 times / day Co-administed with:: antistin(50 mg; 11 days) Sources: |
unhealthy, 49 years n = 1 Health Status: unhealthy Condition: chronic allergic rhinitis Age Group: 49 years Sex: F Population Size: 1 Sources: |
|
Back pain | 25 mg 3 times / day multiple, oral Studied dose Dose: 25 mg, 3 times / day Route: oral Route: multiple Dose: 25 mg, 3 times / day Co-administed with:: antistin(50 mg; 11 days) Sources: |
unhealthy, 49 years n = 1 Health Status: unhealthy Condition: chronic allergic rhinitis Age Group: 49 years Sex: F Population Size: 1 Sources: |
|
Coma | 25 mg 3 times / day multiple, oral Studied dose Dose: 25 mg, 3 times / day Route: oral Route: multiple Dose: 25 mg, 3 times / day Co-administed with:: antistin(50 mg; 11 days) Sources: |
unhealthy, 49 years n = 1 Health Status: unhealthy Condition: chronic allergic rhinitis Age Group: 49 years Sex: F Population Size: 1 Sources: |
|
Common cold | 25 mg 3 times / day multiple, oral Studied dose Dose: 25 mg, 3 times / day Route: oral Route: multiple Dose: 25 mg, 3 times / day Co-administed with:: antistin(50 mg; 11 days) Sources: |
unhealthy, 49 years n = 1 Health Status: unhealthy Condition: chronic allergic rhinitis Age Group: 49 years Sex: F Population Size: 1 Sources: |
|
Diarrhoea | 25 mg 3 times / day multiple, oral Studied dose Dose: 25 mg, 3 times / day Route: oral Route: multiple Dose: 25 mg, 3 times / day Co-administed with:: antistin(50 mg; 11 days) Sources: |
unhealthy, 49 years n = 1 Health Status: unhealthy Condition: chronic allergic rhinitis Age Group: 49 years Sex: F Population Size: 1 Sources: |
|
Disorientation | 25 mg 3 times / day multiple, oral Studied dose Dose: 25 mg, 3 times / day Route: oral Route: multiple Dose: 25 mg, 3 times / day Co-administed with:: antistin(50 mg; 11 days) Sources: |
unhealthy, 49 years n = 1 Health Status: unhealthy Condition: chronic allergic rhinitis Age Group: 49 years Sex: F Population Size: 1 Sources: |
|
Dry cough | 25 mg 3 times / day multiple, oral Studied dose Dose: 25 mg, 3 times / day Route: oral Route: multiple Dose: 25 mg, 3 times / day Co-administed with:: antistin(50 mg; 11 days) Sources: |
unhealthy, 49 years n = 1 Health Status: unhealthy Condition: chronic allergic rhinitis Age Group: 49 years Sex: F Population Size: 1 Sources: |
|
Nausea | 25 mg 3 times / day multiple, oral Studied dose Dose: 25 mg, 3 times / day Route: oral Route: multiple Dose: 25 mg, 3 times / day Co-administed with:: antistin(50 mg; 11 days) Sources: |
unhealthy, 49 years n = 1 Health Status: unhealthy Condition: chronic allergic rhinitis Age Group: 49 years Sex: F Population Size: 1 Sources: |
|
Pyrexia | 25 mg 3 times / day multiple, oral Studied dose Dose: 25 mg, 3 times / day Route: oral Route: multiple Dose: 25 mg, 3 times / day Co-administed with:: antistin(50 mg; 11 days) Sources: |
unhealthy, 49 years n = 1 Health Status: unhealthy Condition: chronic allergic rhinitis Age Group: 49 years Sex: F Population Size: 1 Sources: |
|
Vomiting | 25 mg 3 times / day multiple, oral Studied dose Dose: 25 mg, 3 times / day Route: oral Route: multiple Dose: 25 mg, 3 times / day Co-administed with:: antistin(50 mg; 11 days) Sources: |
unhealthy, 49 years n = 1 Health Status: unhealthy Condition: chronic allergic rhinitis Age Group: 49 years Sex: F Population Size: 1 Sources: |
|
Abdominal pain | grade 3 | 25 mg 3 times / day multiple, oral Studied dose Dose: 25 mg, 3 times / day Route: oral Route: multiple Dose: 25 mg, 3 times / day Co-administed with:: antistin(50 mg; 11 days) Sources: |
unhealthy, 49 years n = 1 Health Status: unhealthy Condition: chronic allergic rhinitis Age Group: 49 years Sex: F Population Size: 1 Sources: |
Headache | grade 3 | 25 mg 3 times / day multiple, oral Studied dose Dose: 25 mg, 3 times / day Route: oral Route: multiple Dose: 25 mg, 3 times / day Co-administed with:: antistin(50 mg; 11 days) Sources: |
unhealthy, 49 years n = 1 Health Status: unhealthy Condition: chronic allergic rhinitis Age Group: 49 years Sex: F Population Size: 1 Sources: |
Nose dryness | 2.2% | 50 mg 3 times / day multiple, oral Recommended Dose: 50 mg, 3 times / day Route: oral Route: multiple Dose: 50 mg, 3 times / day Sources: |
unhealthy, median age 36 years n = 90 Health Status: unhealthy Condition: chronic allergic rhinitis Age Group: median age 36 years Sex: M+F Population Size: 90 Sources: |
Nausea | 4.4% | 50 mg 3 times / day multiple, oral Recommended Dose: 50 mg, 3 times / day Route: oral Route: multiple Dose: 50 mg, 3 times / day Sources: |
unhealthy, median age 36 years n = 90 Health Status: unhealthy Condition: chronic allergic rhinitis Age Group: median age 36 years Sex: M+F Population Size: 90 Sources: |
Dizziness | 5.5% | 50 mg 3 times / day multiple, oral Recommended Dose: 50 mg, 3 times / day Route: oral Route: multiple Dose: 50 mg, 3 times / day Sources: |
unhealthy, median age 36 years n = 90 Health Status: unhealthy Condition: chronic allergic rhinitis Age Group: median age 36 years Sex: M+F Population Size: 90 Sources: |
Sedation | grade 1, 8.9% | 50 mg 3 times / day multiple, oral Recommended Dose: 50 mg, 3 times / day Route: oral Route: multiple Dose: 50 mg, 3 times / day Sources: |
unhealthy, median age 36 years n = 90 Health Status: unhealthy Condition: chronic allergic rhinitis Age Group: median age 36 years Sex: M+F Population Size: 90 Sources: |
Sedation | grade 2, 6.7% | 50 mg 3 times / day multiple, oral Recommended Dose: 50 mg, 3 times / day Route: oral Route: multiple Dose: 50 mg, 3 times / day Sources: |
unhealthy, median age 36 years n = 90 Health Status: unhealthy Condition: chronic allergic rhinitis Age Group: median age 36 years Sex: M+F Population Size: 90 Sources: |
PubMed
Title | Date | PubMed |
---|---|---|
Enhancement of morphine-induced hyperactivity by antihistaminic drugs in mice. | 1986 Dec |
|
Behavioral and developmental effects of prenatal exposure to pentazocine and tripelennamine combinations. | 1986 Nov-Dec |
|
Antihistaminic-opioid combination: effect on locomotor activity in mice. | 1988 Sep-Oct |
|
Effects of antihistaminics on locomotor activity in mice. Comparison with opiate and amphetamine-induced hyperactivity. | 1991 |
|
H1-receptor antagonist, tripelennamine, does not affect arterial hypoxemia in exercising Thoroughbreds. | 2002 Apr |
|
Does the neurotransmitter transporter underlie adaptation at a histaminergic photoreceptor synapse? | 2002 May-Jun |
|
Synthesis and pharmacological identification of neutral histamine H1-receptor antagonists. | 2003 Dec 18 |
|
Medicinal plants in Suriname: hypotensive effect of Gossypium barbadense. | 2004 Mar |
|
Inappropriate prescribing in the hospitalized elderly patient: defining the problem, evaluation tools, and possible solutions. | 2010 Apr 7 |
|
Development of a list of potentially inappropriate drugs for the korean elderly using the delphi method. | 2010 Dec |
|
Profiling of a prescription drug library for potential renal drug-drug interactions mediated by the organic cation transporter 2. | 2011 Jul 14 |
Patents
Sample Use Guides
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/15428185
Unknown
Substance Class |
Chemical
Created
by
admin
on
Edited
Sat Dec 16 16:29:16 GMT 2023
by
admin
on
Sat Dec 16 16:29:16 GMT 2023
|
Record UNII |
3C5ORO99TY
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English | ||
|
Code | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
WHO-ATC |
R06AC04
Created by
admin on Sat Dec 16 16:29:17 GMT 2023 , Edited by admin on Sat Dec 16 16:29:17 GMT 2023
|
||
|
WHO-VATC |
QR06AC04
Created by
admin on Sat Dec 16 16:29:17 GMT 2023 , Edited by admin on Sat Dec 16 16:29:17 GMT 2023
|
||
|
NCI_THESAURUS |
C29578
Created by
admin on Sat Dec 16 16:29:17 GMT 2023 , Edited by admin on Sat Dec 16 16:29:17 GMT 2023
|
||
|
WHO-VATC |
QD04AA04
Created by
admin on Sat Dec 16 16:29:17 GMT 2023 , Edited by admin on Sat Dec 16 16:29:17 GMT 2023
|
||
|
WHO-ATC |
D04AA04
Created by
admin on Sat Dec 16 16:29:17 GMT 2023 , Edited by admin on Sat Dec 16 16:29:17 GMT 2023
|
||
|
CFR |
21 CFR 556.741
Created by
admin on Sat Dec 16 16:29:17 GMT 2023 , Edited by admin on Sat Dec 16 16:29:17 GMT 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
3C5ORO99TY
Created by
admin on Sat Dec 16 16:29:17 GMT 2023 , Edited by admin on Sat Dec 16 16:29:17 GMT 2023
|
PRIMARY | |||
|
TRIPELENNAMINE
Created by
admin on Sat Dec 16 16:29:17 GMT 2023 , Edited by admin on Sat Dec 16 16:29:17 GMT 2023
|
PRIMARY | |||
|
DTXSID8023717
Created by
admin on Sat Dec 16 16:29:17 GMT 2023 , Edited by admin on Sat Dec 16 16:29:17 GMT 2023
|
PRIMARY | |||
|
118946
Created by
admin on Sat Dec 16 16:29:17 GMT 2023 , Edited by admin on Sat Dec 16 16:29:17 GMT 2023
|
PRIMARY | |||
|
1548
Created by
admin on Sat Dec 16 16:29:17 GMT 2023 , Edited by admin on Sat Dec 16 16:29:17 GMT 2023
|
PRIMARY | |||
|
91-81-6
Created by
admin on Sat Dec 16 16:29:17 GMT 2023 , Edited by admin on Sat Dec 16 16:29:17 GMT 2023
|
PRIMARY | |||
|
5587
Created by
admin on Sat Dec 16 16:29:17 GMT 2023 , Edited by admin on Sat Dec 16 16:29:17 GMT 2023
|
PRIMARY | |||
|
SUB11322MIG
Created by
admin on Sat Dec 16 16:29:17 GMT 2023 , Edited by admin on Sat Dec 16 16:29:17 GMT 2023
|
PRIMARY | |||
|
10847
Created by
admin on Sat Dec 16 16:29:17 GMT 2023 , Edited by admin on Sat Dec 16 16:29:17 GMT 2023
|
PRIMARY | RxNorm | ||
|
2762
Created by
admin on Sat Dec 16 16:29:17 GMT 2023 , Edited by admin on Sat Dec 16 16:29:17 GMT 2023
|
PRIMARY | |||
|
CHEMBL1241
Created by
admin on Sat Dec 16 16:29:17 GMT 2023 , Edited by admin on Sat Dec 16 16:29:17 GMT 2023
|
PRIMARY | |||
|
Tripelennamine
Created by
admin on Sat Dec 16 16:29:17 GMT 2023 , Edited by admin on Sat Dec 16 16:29:17 GMT 2023
|
PRIMARY | |||
|
3C5ORO99TY
Created by
admin on Sat Dec 16 16:29:17 GMT 2023 , Edited by admin on Sat Dec 16 16:29:17 GMT 2023
|
PRIMARY | |||
|
m11180
Created by
admin on Sat Dec 16 16:29:17 GMT 2023 , Edited by admin on Sat Dec 16 16:29:17 GMT 2023
|
PRIMARY | Merck Index | ||
|
D014309
Created by
admin on Sat Dec 16 16:29:17 GMT 2023 , Edited by admin on Sat Dec 16 16:29:17 GMT 2023
|
PRIMARY | |||
|
C61991
Created by
admin on Sat Dec 16 16:29:17 GMT 2023 , Edited by admin on Sat Dec 16 16:29:17 GMT 2023
|
PRIMARY | |||
|
202-100-1
Created by
admin on Sat Dec 16 16:29:17 GMT 2023 , Edited by admin on Sat Dec 16 16:29:17 GMT 2023
|
PRIMARY | |||
|
DB00792
Created by
admin on Sat Dec 16 16:29:17 GMT 2023 , Edited by admin on Sat Dec 16 16:29:17 GMT 2023
|
PRIMARY | |||
|
100000076931
Created by
admin on Sat Dec 16 16:29:17 GMT 2023 , Edited by admin on Sat Dec 16 16:29:17 GMT 2023
|
PRIMARY | |||
|
5191
Created by
admin on Sat Dec 16 16:29:17 GMT 2023 , Edited by admin on Sat Dec 16 16:29:17 GMT 2023
|
PRIMARY | |||
|
7318
Created by
admin on Sat Dec 16 16:29:17 GMT 2023 , Edited by admin on Sat Dec 16 16:29:17 GMT 2023
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
SALT/SOLVATE -> PARENT | |||
|
SALT/SOLVATE -> PARENT | |||
|
METABOLIC ENZYME -> SUBSTRATE | |||
|
TARGET -> INHIBITOR |
Related Record | Type | Details | ||
---|---|---|---|---|
|
METABOLITE -> PARENT | |||
|
METABOLITE -> PARENT |
MINOR
URINE
|
||
|
METABOLITE -> PARENT |
MAJOR
URINE
|
||
|
METABOLITE -> PARENT |
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |